Scott T. Tagawa, MD, Weill Cornell Medicine/New York-Presbyterian, discusses updated results from the IMMU-132 trial in metastatic urothelial cancer (mUC).

In the study, patients who were pretreated with platinum-containing chemotherapy received IMMU-132, an anti-Trop-2-SN-38 antibody-drug conjugate.

Of 44 patients, 36 are evaluable for response—which met the primary endpoint. At the time of these results, the response rate is above 30% and durable.

View more from the 2017 Genitourinary Cancers Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Dr. Tagawa on IMMU-132 Trial Updates in Urothelial Cancer